Groupama Asset Managment Buys 9,062 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Groupama Asset Managment lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 80,339 shares of the biopharmaceutical company’s stock after acquiring an additional 9,062 shares during the quarter. Groupama Asset Managment’s holdings in Regeneron Pharmaceuticals were worth $56,445,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Trexquant Investment LP grew its position in Regeneron Pharmaceuticals by 305.9% in the 4th quarter. Trexquant Investment LP now owns 56,625 shares of the biopharmaceutical company’s stock worth $40,336,000 after purchasing an additional 42,674 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 6.8% in the 4th quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company’s stock worth $1,726,940,000 after buying an additional 155,369 shares during the last quarter. Franklin Resources Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 7.9% in the 4th quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company’s stock worth $1,456,864,000 after buying an additional 149,124 shares during the last quarter. Cannell & Spears LLC grew its holdings in shares of Regeneron Pharmaceuticals by 50.9% in the fourth quarter. Cannell & Spears LLC now owns 16,055 shares of the biopharmaceutical company’s stock valued at $11,436,000 after acquiring an additional 5,415 shares in the last quarter. Finally, Alliancebernstein L.P. increased its position in shares of Regeneron Pharmaceuticals by 7.5% during the fourth quarter. Alliancebernstein L.P. now owns 623,156 shares of the biopharmaceutical company’s stock valued at $443,893,000 after acquiring an additional 43,638 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on REGN. Wells Fargo & Company cut their price objective on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research report on Friday, January 10th. TD Cowen cut their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th. Truist Financial decreased their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $762.00 to $834.00 in a research note on Wednesday, February 5th. Finally, UBS Group lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $966.88.

Regeneron Pharmaceuticals Trading Down 0.5 %

Shares of REGN opened at $634.23 on Tuesday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $618.51 and a twelve month high of $1,211.20. The stock has a market cap of $69.34 billion, a PE ratio of 16.57, a P/E/G ratio of 2.34 and a beta of 0.27. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The business’s 50-day moving average price is $682.93 and its 200-day moving average price is $791.84.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the previous year, the company earned $11.86 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% on a year-over-year basis. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were given a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.56%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.